Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated interferon α-2b plus nucleos(t)ide analogues in chronic hepatitis B patients with low-level HBsAg
ChiCTR2500106400Phase 4Not yet recruiting
- Sponsor
- Deyang Cancer Hospital
- Start
- Jul 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Deyang Cancer Hospital. Primary endpoints: Changes in intrahepatic cccDNA compared with baseline, Changes in intrahepatic integrated HBV DNA compared with baseline and 6 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2500106400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106400.